These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20359658)

  • 1. Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
    Ravaud A; Grossgoupil M
    Lancet Oncol; 2010 Apr; 11(4):307-8. PubMed ID: 20359658
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute aortic dissection during sorafenib-containing therapy.
    Serrano C; Suárez C; Andreu J; Carles J
    Ann Oncol; 2010 Jan; 21(1):181-2. PubMed ID: 19858082
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
    Staehler M; Haseke N; Roosen A; Stadler T; Bader M; Siebels M; Karl A; Stief CG
    Eur J Med Res; 2010; 15(7):287-91. PubMed ID: 20696639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
    Flaherty KT
    Cancer; 2010 Jan; 116(1):4-7. PubMed ID: 19890962
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    Di Lorenzo G; Autorino R
    J Urol; 2010 Feb; 183(2):824-5; author reply 825. PubMed ID: 20022057
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib in locally advanced or metastatic breast cancer.
    Gradishar WJ
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1177-91. PubMed ID: 22616580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Verzoni E; Lanocita R; Procopio G
    Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
    Kim C; Lee JL; Choi YH; Kang BW; Ryu MH; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Feb; 30(1):306-15. PubMed ID: 20839031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
    Porta C; Paglino C
    BJU Int; 2011 Mar; 107(5):747-748. PubMed ID: 21355979
    [No Abstract]   [Full Text] [Related]  

  • 12. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
    Richey SL; Ng C; Lim ZD; Jonasch E; Tannir NM
    J Clin Oncol; 2011 Mar; 29(8):e203-5. PubMed ID: 21172884
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
    Williet N; Dubreuil O; Boussaha T; Trouilloud I; Landi B; Housset M; Botti M; Rougier P; Belghiti J; Taieb J
    World J Gastroenterol; 2011 May; 17(17):2255-8. PubMed ID: 21633538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
    Oudard S
    Anticancer Res; 2010 Dec; 30(12):5223-5. PubMed ID: 21187517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic chemotherapy for metastatic renal cell carcinoma.
    Stadler WM
    Urologe A; 2004 Sep; 43 Suppl 3():S145-6. PubMed ID: 15164180
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequential sorafenib and sunitinib for renal cell carcinoma.
    Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
    J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM; Plowman PN; Reznek R; Ball SA
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract]   [Full Text] [Related]  

  • 18. [Targeted therapy - point blank or single shot].
    Rübben H
    Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
    [No Abstract]   [Full Text] [Related]  

  • 19. Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
    Reddy GK; Bukowski RM
    Clin Genitourin Cancer; 2006 Mar; 4(4):246-8. PubMed ID: 16729906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
    Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.